Zydus Lifesciences, a leading Indian pharmaceutical company, has announced that it will acquire LiqMeds Group, a company specializing in oral liquid products, for ₹689 crore. The acquisition is expected to be completed within 10 working days.
LiqMeds Group is a UK-based company with a strong presence in the global oral liquid products market. The company has a portfolio of over 100 products, including antibiotics, antihistamines, and pain relievers. LiqMeds Group also has development, manufacturing, and supply capabilities for global markets.
The acquisition of LiqMeds Group is a significant development for Zydus Lifesciences, as it will give the company access to a strong portfolio of oral liquid products and a global manufacturing and supply chain. The acquisition is also expected to help Zydus Lifesciences expand its reach in the global pharmaceutical market.
Zydus Lifesciences is one of the leading pharmaceutical companies in India, with a strong presence in the domestic and international markets. The company has a diversified portfolio of products, including generics, branded generics, and biopharmaceuticals. Zydus Lifesciences is also known for its strong research and development capabilities.
The acquisition of LiqMeds Group is a positive development for the Indian pharmaceutical industry. It demonstrates the growing strength of Indian pharmaceutical companies and their ability to compete in the global market. The acquisition is also expected to help Zydus Lifesciences expand its market share and become a more global player in the pharmaceutical industry.